JP2006515004A5 - - Google Patents

Download PDF

Info

Publication number
JP2006515004A5
JP2006515004A5 JP2005518422A JP2005518422A JP2006515004A5 JP 2006515004 A5 JP2006515004 A5 JP 2006515004A5 JP 2005518422 A JP2005518422 A JP 2005518422A JP 2005518422 A JP2005518422 A JP 2005518422A JP 2006515004 A5 JP2006515004 A5 JP 2006515004A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
formula
pharmaceutically acceptable
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2005518422A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006515004A (ja
Filing date
Publication date
Priority claimed from GBGB0303319.8A external-priority patent/GB0303319D0/en
Application filed filed Critical
Publication of JP2006515004A publication Critical patent/JP2006515004A/ja
Publication of JP2006515004A5 publication Critical patent/JP2006515004A5/ja
Ceased legal-status Critical Current

Links

JP2005518422A 2003-02-13 2004-02-12 インドリルマレイミド誘導体 Ceased JP2006515004A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0303319.8A GB0303319D0 (en) 2003-02-13 2003-02-13 Organic compounds
PCT/EP2004/001323 WO2004072062A2 (en) 2003-02-13 2004-02-12 Indolylmaleimide derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009165725A Division JP2009280592A (ja) 2003-02-13 2009-07-14 インドリルマレイミド誘導体

Publications (2)

Publication Number Publication Date
JP2006515004A JP2006515004A (ja) 2006-05-18
JP2006515004A5 true JP2006515004A5 (cg-RX-API-DMAC7.html) 2009-09-03

Family

ID=9952961

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2005518422A Ceased JP2006515004A (ja) 2003-02-13 2004-02-12 インドリルマレイミド誘導体
JP2009165725A Pending JP2009280592A (ja) 2003-02-13 2009-07-14 インドリルマレイミド誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009165725A Pending JP2009280592A (ja) 2003-02-13 2009-07-14 インドリルマレイミド誘導体

Country Status (12)

Country Link
US (1) US7820672B2 (cg-RX-API-DMAC7.html)
EP (2) EP1597250B8 (cg-RX-API-DMAC7.html)
JP (2) JP2006515004A (cg-RX-API-DMAC7.html)
CN (1) CN100439359C (cg-RX-API-DMAC7.html)
AT (2) ATE551335T1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0407512A (cg-RX-API-DMAC7.html)
CA (1) CA2513613A1 (cg-RX-API-DMAC7.html)
DE (1) DE602004026415D1 (cg-RX-API-DMAC7.html)
ES (2) ES2385071T3 (cg-RX-API-DMAC7.html)
GB (1) GB0303319D0 (cg-RX-API-DMAC7.html)
PT (1) PT1597250E (cg-RX-API-DMAC7.html)
WO (1) WO2004072062A2 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246346B1 (en) 2005-07-11 2012-10-24 Novartis AG Indolylmaleimide derivatives as protein kinase inhibitors
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
JP2010513386A (ja) 2006-12-19 2010-04-30 ノバルティス アーゲー キナーゼ阻害剤としてのインドリルマレイミド誘導体
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN101671329B (zh) * 2009-06-17 2012-11-07 东华大学 3-氨基醇取代的吲哚马来酰亚胺化合物、其制备和应用
US9724331B2 (en) 2012-12-10 2017-08-08 Centogene Ag Use of maleimide derivatives for preventing and treating leukemia
CN104693198B (zh) * 2014-12-13 2017-03-08 浙江工业大学 3‑(1,2,4‑三氮唑并[4,3‑a]吡啶‑3‑基)‑4‑(1H‑吲哚‑3‑基)马来酰亚胺类衍生物及其制备方法和应用
EP3292152A1 (en) 2015-05-07 2018-03-14 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
WO2017096179A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
WO2018132636A1 (en) * 2017-01-12 2018-07-19 The Research Foundation For The State University Of New York [18f]maleimide-based glycogen synthase kinase-3beta ligands for positron emission tomography imaging and radiosynthesis method
CN110551103B (zh) * 2018-05-30 2022-08-23 北京大学深圳研究生院 一种jak3选择性抑制剂
WO2020163812A1 (en) 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0629947B2 (ja) 1986-07-16 1994-04-20 正浩 入江 光学記録材料
CZ280738B6 (cs) 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
DE4005970A1 (de) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
GB9123396D0 (en) 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
AU3761393A (en) 1992-03-20 1993-10-21 Wellcome Foundation Limited, The Indole derivatives with antiviral activity
JPH06161024A (ja) 1992-11-26 1994-06-07 Sanyo Electric Co Ltd 光学記録材料
US5405864A (en) * 1993-10-15 1995-04-11 Syntex (U.S.A.) Inc. Chemotherapeutic maleimides
US5559228A (en) * 1995-03-30 1996-09-24 Eli Lilly And Company Synthesis of bisindolylmaleimides
JPH0961647A (ja) 1995-08-25 1997-03-07 Nippon Telegr & Teleph Corp <Ntt> 光素子用有機材料
FR2772266B1 (fr) 1997-12-12 2000-02-04 Oreal Utilisation d'agent de coloration photochrome dans une composition cosmetique, et composition cosmetique le comprenant
JP2002527419A (ja) 1998-10-08 2002-08-27 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Gsk−3阻害物質としてのピロール−2,5−ジオン類
GB9828640D0 (en) 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
DE10042603B4 (de) 1999-08-31 2010-04-29 Kyocera Corp. Photochrome Verbindung und ihre Verwendung in optischen Funktionsvorrichtungen
AU1189201A (en) 1999-10-22 2001-05-08 Eli Lilly And Company Therapeutic compositions including protein kinase c inhibitors
US6281356B1 (en) 1999-12-22 2001-08-28 Hoffmann-La Roche Inc. Substituted pyrroles
DE60129222T2 (de) 2000-05-11 2008-03-06 Consejo Superior de Investigaciónes Científicas Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3
CA2417277A1 (en) 2000-07-27 2002-02-07 F. Hoffmann-La Roche Ag 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3.beta.
CN1253449C (zh) 2000-11-07 2006-04-26 诺瓦提斯公司 作为蛋白激酶c抑制剂的吲哚基马来酰亚胺衍生物
JP2002285146A (ja) 2001-03-27 2002-10-03 Masahiro Irie フォトクロミック組成物及び線量計
AU2002249103A1 (en) 2001-03-29 2002-10-15 Topo Target Aps Succinimide and maleimide derivatives and their use as topoisomerase ii catalytic inhibitors
BE1014306A6 (fr) 2001-07-19 2003-08-05 Project 21C Dispositif de stationnement d'un cycle avec antivol.
ATE368657T1 (de) * 2002-03-08 2007-08-15 Lilly Co Eli Pyrrol-2,5-dion derivate und deren verwendung als gsk-3 inhibitoren
AR039209A1 (es) * 2002-04-03 2005-02-09 Novartis Ag Derivados de indolilmaleimida

Similar Documents

Publication Publication Date Title
EP2429986B1 (en) Haloalkyl heteroaryl benzamide compounds
EP2877457B1 (en) Cystathionine-gamma-lyase (cse) inhibitors
JP4792025B2 (ja) 5−ヒドロキシインドール−3−カルボン酸エステル類誘導体およびその用途
JP6021805B2 (ja) 腫瘍治療剤
AU2021246118B2 (en) Methods of treating coronavirus
JP2006523216A5 (cg-RX-API-DMAC7.html)
WO2007139150A1 (ja) TNFα阻害物質を含有してなる抗インフルエンザウイルス剤
JP2005506368A (ja) 肥満の処置におけるまたは食物摂取の減少のためのインドールおよびインドリン誘導体の使用
US20200323828A1 (en) Methods of treating behavior alterations
US12064410B2 (en) Compositions and methods for stimulating ventilatory and/or respiratory
WO2019046287A1 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HEPATITIS B
CN100361975C (zh) 5-羟基-3-羧酸酯吲哚类衍生物及其制备方法
JP4034849B2 (ja) 慢性腺維形成性肝疾患、急性肝疾患およびそれに関わる合併症の治療および予防のための非ペプチドブラジキニン拮抗剤の使用
US6455567B1 (en) Method of treatment
HUP0002966A2 (hu) Alfa-2-adrenoreceptor agonistákként alkalmazható [(2-imidazolidinilidén)-amino]-benzoxazol-származékok és az ezeket tartalmazó gyógyszerkészítmények
JP2019535680A (ja) キナーゼを阻害する組成物及び方法
JP7535797B2 (ja) 化合物バフィデムスタット(vafidemstat)などkdm1a阻害剤を使用した注意欠陥多動性障害の処置方法
JP2007507472A5 (cg-RX-API-DMAC7.html)
CN101663035B (zh) 4-环丙基甲氧基-n-(3,5-二氯代-1-氧化-吡啶-4-基)-5-(甲氧基)吡啶-2-甲酰胺在制备用于治疗与帕金森症有关的运动障碍的药物中的用途
US20070004777A1 (en) Methods for treating or preventing acute myelogenous leukemia
CN100584828C (zh) 新的5-羟基吲哚-3-羧酸酯类衍生物
US10543187B2 (en) Compositions and methods for stimulating ventilatory and/or respiratory drive
CN101663036B (zh) 4-环丙基甲氧基-n-(3,5-二氯代-1-氧代-4-吡啶-4-基)-5-(甲氧基)吡啶-2-甲酰胺用于治疗颅脑创伤的用途
CN100519523C (zh) 5-羟基吲哚-3-羧酸酯类衍生物及其用途
JP2004002272A (ja) 2型糖尿病治療剤